ReviewCancers2021
The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.Cancer discovery · 2023Trial
- Microbiome and cancer immunotherapy: a bibliometric analysis.Journal of the Egyptian National Cancer Institute · 2026Article
- Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy.Chinese medical journal · 2026Review
- Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications.Cancer medicine · 2026Review
- Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity.International journal of molecular sciences · 2026Review
- The role of gut microbiota in liver metastasis of small cell lung cancer: mechanisms and therapeutic implications.Frontiers in cellular and infection microbiology · 2026Review
- A Novel Prognostic Model Based on Prognostic Nutritional Index and Systemic Immune-Inflammation Index for Cancer Patients Treated with Immune Checkpoint Inhibitors.Cancer management and research · 2026Article
- Important Role of Bacterial Metabolites in Development and Adjuvant Therapy for Hepatocellular Carcinoma.Current oncology (Toronto, Ont.) · 2025Review
- Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review.Medicina (Kaunas, Lithuania) · 2025Review
- Tumor Microenvironment in Melanoma-Characteristic and Clinical Implications.International journal of molecular sciences · 2025Review
- Gastric Cancer and Microbiota: Exploring the Microbiome's Role in Carcinogenesis and Treatment Strategies.Life (Basel, Switzerland) · 2025Review
- Immune checkpoint inhibitors: From friend to foe.Toxicology reports · 2025Article
- Prioritizing gut microbial SNPs linked to immunotherapy outcomes in NSCLC patients by integrative bioinformatics analysis.Journal of translational medicine · 2025Article
- Gut microbiota and metabolites: emerging prospects in the treatment of non-small cell lung cancer.Frontiers in immunology · 2025Review
- Therapeutic targeting of the host-microbiota-immune axis: implications for precision health.Frontiers in immunology · 2025Review
- Gut Microbial Dysbiosis and Implications in Solid Organ Transplantation.Biomedicines · 2024Review
- Gut microbiota and metabolites associated with immunotherapy efficacy in extensive-stage small cell lung cancer: a pilot study.Journal of thoracic disease · 2024Article
- Immune checkpoint inhibitor-induced diarrhea and colitis: an overview.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Review
- Implications of intestinal microecology and immune function alterations for immunotherapy outcomes in advanced unresectable lung adenocarcinoma.The clinical respiratory journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.